Skip to main content
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. logo

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. — Investor Relations & Filings

Ticker · 301130 ISIN · CNE1000058C4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 545 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 301130

About Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd.

https://www.xidianyy.com

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. focuses on the research, development, manufacturing, and distribution of pharmaceutical products. The company specializes in biochemical drugs, the modernization of traditional Chinese medicine, and chemical pharmaceuticals. Its core product portfolio includes treatments for cardiovascular and cerebrovascular diseases, anti-viral medications, and anti-tumor therapies. Xidian Pharmaceutical emphasizes scientific innovation and technological advancement to enhance drug efficacy and safety. The company operates production facilities compliant with Good Manufacturing Practice (GMP) standards and maintains a distribution network serving healthcare providers and pharmacies.

Recent filings

Filing Released Lang Actions
关于吉林省西点药业科技发展股份有限公司2025年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter by counsel on the company’s 2025 Annual General Meeting, detailing the meeting’s convening procedures and, critically, the voting results on each agenda item. It is not the AGM materials themselves nor a full annual report—rather, it officially declares vote outcomes at the shareholders’ meeting. This aligns with Declaration of Voting Results (DVA).
2026-05-21 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is an official announcement of the resolutions and voting results from the company’s 2025 Annual General Meeting (AGM), detailing attendance, vote counts (for/against/abstain) on multiple proposals, and legal opinions. This matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category.
2026-05-21 Chinese
关于子公司维生素B6注射液获得药品注册证书的公告
Regulatory Filings Classification · 87% confidence The document is a corporate announcement in Chinese about the subsidiary obtaining a drug registration certificate from the National Medical Products Administration. It is not a financial report, earnings release, management change, or proxy statement. It serves as a general regulatory announcement related to a product approval. Therefore, it falls under the catch-all category for miscellaneous regulatory disclosures.
2026-05-20 Chinese
关于参加2026年吉林辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 90% confidence The document is a public announcement by the company about participating in an online investor reception day event, rather than the actual investor presentation materials, financial statements, or an AGM notice. It does not fit any specific category like IR, 10-K, ER, MANG, or CAP. It is therefore best classified as a general regulatory announcement (RNS).
2026-05-15 Chinese
关于持股5%以上股东及其一致行动人减持股份触及1%整数倍的公告
Major Shareholding Notification Classification · 88% confidence The document is an announcement by a listed company regarding a reduction in shareholding by a >5% shareholder (and its concert parties), triggering a 1% threshold. It provides detailed pre- and post-change holdings, ratio changes, and compliance statements. This fits the definition of a Major Shareholding Notification (MRQ), not a company repurchase, board change, or earnings report.
2026-05-11 Chinese
关于首次回购公司股份暨回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 吉林省西点药业科技发展股份有限公司 regarding the company's first share repurchase and the progress of the share buyback plan. It details the intended amount for repurchase, the price limits, the approval by the board, and the actual shares repurchased as of a certain date. The document does not contain financial statements or detailed financial analysis but focuses on the share repurchase activity and compliance with regulatory rules. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2026-03-02 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.